Steerable Punch (Foto: Surge-on Medical)
Frankfurt am Main, Delft (pta007/15.01.2020/07:15) - Dutch MedTech company has already raised over EUR 500,000 in first pan-European digital venture fundraising on aescuvest.eu
After passing the initial funding goal of EUR 500,000 in December, Surge-on Medical B.V. has decided to extend the campaign to attract further investments. The Dutch MedTech start-up is developing and selling revolutionary surgical instruments for minimal invasive arthroscopy and laparoscopy that are fully steerable, swiftly detachable and easy to clean. Its CEO Benno Groosman stated: "We are very happy that we have reached our first goal. The proceeds of the first campaign phase enable us to obtain the Class I CE mark for the Steerable Punch. With that in place, we will be able to start the large-scale manufacturing in order to satisfy the existing demand from European distributors." In addition, Surge-on Medical plans to expand its team with special focus on strengthening worldwide sales activities. Commercial relationships with European, South-Korean and Chinese international distributors and hospitals are assessed as key factors for market penetration. The award-winning product also draws increasing interest from UK, Latin American and Australian distribution partners. First product demo batches that were sold in South Korea and in the Netherlands have already generated pre-market launch revenues for the company.
New Funding Platform Set to Foster Innovations from European Healthcare Start-ups and SMEs by European Citizens
The campaign kick-off for Surge-on Medical marks the start of a new way of public venture funding in Europe. aescuvest.eu was launched jointly by aescuvest and EIT Health, the EU-supported health innovation network of approximately 150 partners. Jan-Philipp Beck, CEO of EIT Health commented: "The crowdfunding initiative is quickly gathering speed and we have been extremely pleased with the the success demonstrated to date. We are thrilled that promising European health enterprises are now accessible for Europeans to invest in, and that we are able to play a role in diversifying the funding opportunities available to support European health innovators."
Aescuvest's CEO Dr. Patrick Pfeffer added: "Passing the funding threshold of EUR 500,000 demonstrates both, the interest from investors in Surge-on Medical's business model and the acceptance for a security-based and prospectus-approved high-risk and high-reward investment offering." In the public campaign, which started in late August 2019, so far, 77 backers contributed an average of EUR 7,000 to the successful crowdfunding that attracts professional and retail investors alike. Family offices, boutique investment firms and business angels account for approximately two thirds of those funds. In the initiation period of aescuvest.eu, the minimum investment amount was EUR 500, with the largest single investment amounting to EUR 100,000. So far, individuals and companies from Germany, the Netherlands, Austria, Sweden, Switzerland and the UK contributed to the campaign.
aescuvest is the first pan-European crowdfunding platform exclusively dedicated to the health sector, a dynamic market that is large in size, shows sustained growth rates and is driven by innovation. The platform offers retail investors, business angels and venture capitalists opportunities to make entrepreneurial investments in a promising market with above average returns. For start-up companies it serves as an independent launch pad to finance and market smart ideas, with the potential to directly target up to 550,000 healthcare professionals as well as general public all over Europe. Based in the financial hub of Frankfurt, www.aescuvest.de was started as a platform for crowdfunding campaigns for Germany in 2015, bringing innovations in MedTech, Biotech, Health Service, Digital Health and Health Rentals to life. In 2018, the start of www.aescuvest.eu marked the premier of the first platform to offer cross-border equity crowdfunding for healthcare companies and investors all over Europe: www.aescuvest.eu
EIT Health is a network of best-in-class health innovators with approximately 150 partners and is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. We collaborate across borders to deliver new solutions that can enable European citizens to live longer, healthier lives. As Europeans tackle the challenge of increasing chronic diseases and multi-morbidity, and seek to realise the opportunities that technology offers to move beyond conventional approaches to treatment, prevention and healthy lifestyles, we need thought leaders, innovators and efficient ways to bring innovative healthcare solutions to market. EIT Health addresses these needs. We connect all relevant healthcare players across European borders - making sure to include all sides of the "knowledge triangle", so that innovation can happen at the intersection of research, education and business for the benefit of citizens. For more information visit: www.eithealth.eu
Founded in 2015, Surge-on Medical has developed the next generation of minimally invasive surgical instruments. They are setting new standards to deliver better healthcare. Through cable-free technologies, they have created freedimensional instruments that provide better access to surgical areas and replace current pre-bent instrumentation. Surge-on Medical has been granted four international patents which make minimally invasive instruments steerable, detachable and cleanable. The freedimensional instruments offer cable-free steerability with up to 80% fewer parts. Combined with quick detachability, the instruments can be easily cleaned in standard processes and safely reused. With their multi-patented platform technology, Surge-on Medical is currently active in three markets: arthroscopy, laparoscopy and robotic surgery. www.surge-on.eu
This document is a customer information ("CI") within the meaning of the German Securities Trading Act, the "CI" is intended for natural and legal persons with a habitual residence or registered office in Germany and is used exclusively for information purposes.
This "CI" cannot replace individual investment and investor-oriented advice and does not constitute a contract or any other obligation or any kind of contractual offer. Furthermore, the contents do not constitute investment advice, an individual investment recommendation, an invitation to subscribe to securities or a declaration of intent or invitation to conclude a contract for a transaction in financial instruments. Nor was it written with the intention of providing legal or tax advice. The tax treatment of transactions depends on the personal circumstances of the respective client and may be subject to future changes. The individual circumstances of the recipient (including the economic and financial situation) were not taken into account in the preparation of the "CI".
An investment in the aforementioned financial instruments/investment strategy/financial services involves certain product-specific risks - e.g. market or sector risks, currency, default, liquidity, interest rate and credit risk - and is not suitable for all investors. Therefore, potential investors should only make an investment decision after a detailed investment consultation with a registered investment advisor and after consulting all available sources of information. For further information, you will find the "Essential Investor Information" and the securities prospectus here: www.aescuvest.eu
Past performance is not a reliable indicator of future performance. Recommendations and forecasts represent non-binding value judgements about future events and may therefore prove to be incorrect with regard to the future development of a product. The listed information refers exclusively to the time of the production of this "AI", a guarantee for the topicality and continuing correctness cannot be given. The information provided refers exclusively to the time of preparation of this "CI", no guarantee can be given that it is up to date and continues to be correct.
The above content exclusively reflects the opinions of the author; a change of these opinions is possible at any time without publication. The present "CI" is protected by copyright, any duplication and commercial use is not permitted. Date: 15th January 2020
Publisher:Aescuvest international GmbH, Hanauer Landstr. 328-330, 60314 Frankfurt am Main is acting as a contractually bound agent (§2 section 10 KWG) on behalf, in the name, for the account and under the liability of the responsible liable party BN & Partners Capital AG, Steinstrasse 33, 50374 Erftstadt. BN & Partners Capital AG holds a corresponding license from the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) pursuant to section §32 of the KWG for the provision of investment advice pursuant to §1 section 1a no.1 of the KWG and investment brokerage pursuant to section §1 section 1a no. 1a of the KWG.